Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
10.97
+0.05 (0.46%)
At close: Aug 14, 2026, 4:00 PM EDT
10.77
-0.20 (-1.80%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Immix Biopharma Earnings Call Transcripts

Fiscal Year 2025

  • Status Update

    NXC-201 CAR T-cell therapy shows rapid, deep, and durable responses in relapsed/refractory AL amyloidosis, with a favorable safety profile and potential for outpatient use. If approved, it could address a major unmet need for over 20,000 U.S. patients.